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This is part of a series of occasional articles on common problems in
primary care. The BMJ welcomes contributions from GPs.
A 72 year old woman, who had been diagnosed as having
recurrent deep vein thrombosis six weeks earlier, attends the
practice’s phlebotomy clinic for an international normalised
ratio (INR) check. Her INR is greater than 8.0 (target INR range:
2.0-3.0). During the consultation, you look through her previous
INR readings and notice they have been supra-therapeutic over
the past two weeks despite a reduction in the dose of warfarin.
What you should cover
• Screen for “red flag” symptoms and signs of active,
non-resolving bleeding:
-Use a thorough systems review; in particular look for any
evidence of gastrointestinal bleeding, such as vomiting
blood and passing altered or fresh rectal blood. If ongoing
gastrointestinal bleeding is suspected, inpatient warfarin
reversal and an oesophagogastroduodenoscopy are
indicated
-Any evidence of intracranial bleeding? Ask about recent
head trauma with an episode of amnesia, loss of
consciousness, post-traumatic seizure, or more than one
episode of vomiting. Examine for a reduced Glasgow coma
score as well as focal neurological signs. All patients who
sustain a head injury while taking warfarin require a
computed tomography head scan within eight hours of the
injury, even if these clinical features are absent, according
to guidance from the National Institute for Health and Care
Excellence (NICE).1 However, those with a reduced
Glasgow coma score, focal neurological signs,
post-traumatic seizure, or more than one episode of
vomiting require such a scan within one hour.1
-Check pulse and sitting and standing blood pressure for
evidence of haemodynamic compromise.
• Clarify the doses of warfarin the patient has been taking
because some patients may overmedicate by mistake. If
this is the case, ask how often the patient takes warfarin
and at what dose. Provide appropriate written information
if necessary. A dossette box might help her comply with
the prescribed dose.
• Is there an important medical problem, such as liver disease
or cancer, that might result in impaired synthesis of clotting
factors? Patients with underlying cancer are at a higher risk
of haemorrhage with warfarin than with low molecular
weight heparin. They are also more likely to experience
polypharmacy, hepatic dysfunction, and poor nutrition,
which can influence their INR control. In these patients,
consider using low molecular weight heparin instead.2
• Take a thorough drug history. Ask about prescribed drugs,
over the counter drugs, and herbal supplements. The
cytochrome P450 enzyme metabolises warfarin, so P450
inhibitors can cause the INR to rise. Common inhibitors
of warfarin metabolism include clarithromycin,
erythromycin, and amiodarone—for a comprehensive list
see: www.medicinescomplete.com/mc/bnf/current/bnf_
int222-warfarin.htm. Check the INR three to five days later
after starting any drug that interacts with warfarin that will
be taken for longer than seven days because the dose of
warfarin may need adjusting.3
• Inquire about alcohol. Patients taking warfarin should be
discouraged from binge drinking because large amounts
of alcohol inhibit warfarin breakdown and affect liver
function.
• Ask about changes to diet. Patients may become more
sensitive to warfarin if cutting down on vitamin K rich
foods, such as leafy green vegetables. Encourage the patient
to consult a doctor before major diet changes. Consumption
of fruit juices, particularly cranberry or grapefruit, which
inhibit warfarin metabolism, can cause INR levels to
increase. These juices should be avoided.
If any of the above “red flag” features are present and an active
bleed is suspected, refer to secondary care. If bleeding is
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The bottom line
• Clarify the warfarin dose that the patient is taking, and check for co-existing problems (such as liver disease or cancer), dietary changes,
and intake of alcohol and other drugs that may increase risk of bleeding or affect international normalised ratio control
• Urgently refer all patients with suspected intracranial or gastrointestinal bleeding to secondary care
confirmed in hospital, urgent reversal of warfarin with a four
factor prothrombin complex concentrate may be warranted.
What you should do
If this patient is not actively bleeding she can be managed in
the community (table 1⇓). The British Committee for Standards
in Haematology and The Medicines and Healthcare products
Regulatory Agency advise that patients with an INR >8.0 who
are not bleeding have their warfarin omitted until the INR drops
to <5.0.3 4 They should also be given 1-5 mg oral vitamin K,
which will take up to 24 hours to work.5 Once the INR is <5.0,
restart the patient on a reduced dose of warfarin.
Advice and follow-up
• Highlight the importance of presenting to a medical
practitioner in the case of a head injury or if bleeding does
not resolve with conservative measures.
• After administering vitamin K, ensure that daily INR
checks are organised until the INR is stable within the
target range.
• Patients on long termwarfarin should be reviewed annually
or more often if there is doubt about their safety on
continued anticoagulation.
• If INR continues to be high despite efforts to identify a
precipitating cause, refer to the local hospital
anticoagulation clinic or consider switching to a new oral
anticoagulant such as the factor Xa inhibitor rivaroxaban
after appropriate counselling. The direct thrombin inhibitor
dabigatran is another new oral anticoagulant approved by
the National Institute for Health and Care Excellence
(NICE) for non-valvular atrial fibrillation and recently also
for the treatment of venous thromboembolism. Compared
with warfarin, both dabigatran and rivaroxaban seem to
have fewer interactions with other drugs, so anticoagulant
monitoring is not recommended by the manufacturers,
although this advice remains controversial. Moreover, both
drugs are contraindicated in patients with poor renal
function and the pharmacological actions of these agents
are irreversible in the event of bleeding.6
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Table
Table 1| Summary of the management of supra-therapeutic warfarin levels3 4
Bleeding*Not bleedingINR
Minor: stop warfarin and apply first aid measures; give
1-3 mg intravenous vitamin K if bleeding does not stop
with such measures
Reduce warfarin dose; re-check INR in 48 hours†3.0-5.0
Omit warfarin until INR <5.0, then start reduced dose; re-check
INR in 48 hours†
5.0-8.0
Limb or life threatening: refer to secondary care for
warfarin reversal
Omit warfarin, give 1-5 mg oral vitamin K; re-check INR in 24
hours†
>8.0
*The management of all types of bleeding applies to all INR categories.
†Advice on when to recheck INR values is based on the authors’ experience and the half life of warfarin and vitamin K.
INR=international normalised ratio.
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